Skip to content
MedsAcross

Medicine

Rasuvo 10 mg/0.2 mL injection

Methotrexate · Subcutaneous · Medexus Pharma
Available on requestPrescription onlyUS FDA

Rasuvo 10 mg/0.2 mL injection is a prescription medicine containing Methotrexate for subcutaneous use, marketed by Medexus Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at controlled room temperature, 25°C (77°F), excursions permitted to 15°…

Key facts

Active ingredient (INN)
Methotrexate
Brand
Rasuvo
Strength
10 mg/0.2 mL
Dosage form
Injection
Route
Subcutaneous
Packs
1 package, 4 package and 15 more
Marketing authorisation holder
Medexus Pharma
Manufacturer
Medexus Pharma
Origin register
US FDA, United States
Storage
Store at controlled room temperature, 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). PROTECT FROM LIGHT.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01BA01 Methotrexate
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
10 July 2014
Identifiers
RxCUI 1441416, 1544378, 1544383 +7DailyMed set ID d0075461-0e7e-4967-9c9b-d6440e912c0eNDC 59137-525, 59137-530, 59137-540 +6Application NDA205776

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 package in 1 carton / .15 mL in 1 package59137-505-01Medexus Pharma10 July 2014
4 package in 1 carton / .15 mL in 1 package59137-505-04Medexus Pharma10 July 2014
1 package in 1 carton / .2 mL in 1 package59137-510-01Medexus Pharma10 July 2014
4 package in 1 carton / .2 mL in 1 package59137-510-04Medexus Pharma10 July 2014
1 package in 1 carton / .25 mL in 1 package59137-515-01Medexus Pharma10 July 2014
4 package in 1 carton / .25 mL in 1 package59137-515-04Medexus Pharma10 July 2014
1 package in 1 carton / .3 mL in 1 package59137-520-01Medexus Pharma10 July 2014
4 package in 1 carton / .3 mL in 1 package59137-520-04Medexus Pharma10 July 2014
1 package in 1 carton / .35 mL in 1 package59137-525-01Medexus Pharma10 July 2014
4 package in 1 carton / .35 mL in 1 package59137-525-04Medexus Pharma10 July 2014
1 package in 1 carton / .4 mL in 1 package59137-530-01Medexus Pharma10 July 2014
4 package in 1 carton / .4 mL in 1 package59137-530-04Medexus Pharma10 July 2014
1 package in 1 carton / .45 mL in 1 package59137-535-01Medexus Pharma10 July 2014
4 package in 1 carton / .45 mL in 1 package59137-535-04Medexus Pharma10 July 2014
1 package in 1 carton / .5 mL in 1 package59137-540-01Medexus Pharma10 July 2014
4 package in 1 carton / .5 mL in 1 package59137-540-04Medexus Pharma10 July 2014
1 package in 1 carton / .6 mL in 1 package59137-550-01Medexus Pharma10 July 2014
4 package in 1 carton / .6 mL in 1 package59137-550-04Medexus Pharma10 July 2014

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 7 December 1953Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Methotrexate

Clinical summary

Methotrexate is a folate analog metabolic inhibitor indicated for neoplastic diseases for the, among other approved uses. It is available as injection, tablets and powder for injection for oral, subcutaneous and intramuscular use. MedsAcross supplies Methotrexate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Methotrexate

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Rasuvo 10 mg/0.2 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.